Acción de los anti estrógenos y observaciones en el varón transexual (página 2)

34. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996 Mar 14:3 1018-26

35. Nydick m, bustos j, dale j, rawson r. Gynecomastia in adolescent boys. JAMA 196; 178: 449-54.

36. Oduwole OO, Makinen MJ, Isomaa VV, Pulkka A, Jernvall P, Karttunen TJ, Vihko PT. 17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. Steroid Biochem Mol Biol 2003 Nov; 87(2-3): 133-140

37. Ortiz-Núñez DA, Mengchún-López G, HernándezMarín I, Mendoza R, Ayala-Ruiz AR. Ausenciade efecto antiosteopénico de la terapia hormonal de reemplazo en mujeres posmenopáusicas Ginecol Obstet Mex 2004;72:349-355

38. Osborne CK, Zhao HH, Fuqua SAW. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.

39. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Bertagna C, De Gery A, Hucher M, et al.Comparison of diethystilbestrol, cyproterone acetate, and medroxiprogesterone acetate in the treatement of advanced prostate cáncer

40. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging. 2008;8:135-45.

41. Riepe F, Baus I, Wiest S, Krone N, Sippell W, Partsch C-J. Treatment of Pubertal Gynecomastia with the Specific aromatase Inhibitor Anastrozole. Horm Res 2004; 62: 113-8.

42. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N Engl J Med 2003;348:518-29

43. Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 1996 May 8:5 329-37

44. Rodriguez RC, Esperon AA, Ropero R, Rubio MC, Rodriguez R, Ortiz RM et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer 2008;7: 275-279.

45. Santen RJ. Editorial: Long term tamoxifen therapy: can an antagonist become an agonist? J Clin Endocrinol Metab1996; 81: 2027-2029.

46. Tamimi R, Byrne C, Colditz G, Hankinson S. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007; 99:1178-87.

47. Vachon C, Kuni C, Anderson K, Anderson E, Sellers T. Association of mammographically defined percent breast density with epidemilogic risk factors for breast cancer (United States). Cancer Causes and Control 2000; 11:653-662.

48. Wickerham L, Tan-Chiu E. Quimioprevención del cáncer de mama: estado actual e indicaciones futuras. Semen Oncol 2002; 1(1)35-41